Safety and Efficacy of NPI-002 Intravitreal Implant for the Delay of Cataract Progression in Patients Undergoing Vitrectomy

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Apr 2024 According to a Nacuity Pharmaceuticals media release, company announced that the first patients have been implanted in the final cohort.An independent Data Safety Monitoring Board (DSMB) recommended proceeding with the final cohort after a positive safety review. The final cohort of the trial is actively enrolling patients for clinical sites at The Royal Adelaide Hospital (RAH) in Adelaide, South Australia, and personalEYES in Parramatta, New South Wales, Australia.
07 Feb 2024 Planned End Date changed from 1 Apr 2024 to 1 Feb 2025.
07 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com